256 related articles for article (PubMed ID: 28702469)
1. Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
Muhammed M; Flokas ME; Detsis M; Alevizakos M; Mylonakis E
Open Forum Infect Dis; 2017; 4(2):ofx099. PubMed ID: 28702469
[TBL] [Abstract][Full Text] [Related]
2. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
5. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
Son SK; Lee NR; Ko JH; Choi JK; Moon SY; Joo EJ; Peck KR; Park DA
J Antimicrob Chemother; 2018 Oct; 73(10):2631-2642. PubMed ID: 29800480
[TBL] [Abstract][Full Text] [Related]
7. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
8. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
Zhang H; Liang B; Wang J; Cai Y
Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing
Xiao T; Yang K; Zhou Y; Zhang S; Ji J; Ying C; Shen P; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():144. PubMed ID: 31467670
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Analysis of Risk Factors and Patient Outcomes of Bloodstream Infection with Extended-Spectrum β-Lactamase-Producing
Xiao Y; Hang Y; Chen Y; Fang X; Cao X; Hu X; Luo H; Zhu H; Zhu W; Zhong Q; Hu L
Infect Drug Resist; 2020; 13():4289-4296. PubMed ID: 33262623
[TBL] [Abstract][Full Text] [Related]
11. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials.
Shiber S; Yahav D; Avni T; Leibovici L; Paul M
J Antimicrob Chemother; 2015 Jan; 70(1):41-7. PubMed ID: 25261419
[TBL] [Abstract][Full Text] [Related]
12. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.
Harris PN; Yin M; Jureen R; Chew J; Ali J; Paynter S; Paterson DL; Tambyah PA
Antimicrob Resist Infect Control; 2015; 4():14. PubMed ID: 25932324
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
14. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis.
Jiang AM; Liu N; Zhao R; Zheng HR; Chen X; Fan CX; Zhang R; Zheng XQ; Fu X; Yao Y; Tian T
Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):53. PubMed ID: 33228668
[TBL] [Abstract][Full Text] [Related]
16. [Empirical therapy of bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae].
Tang CQ; Li JQ; Xia ZF; Wang H; Lü KY; Xiao SC; Deng AM; Huang Y
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(26):2076-80. PubMed ID: 27468620
[TBL] [Abstract][Full Text] [Related]
17. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
18. Bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis.
Alevizakos M; Gaitanidis A; Andreatos N; Arunachalam K; Flokas ME; Mylonakis E
Int J Antimicrob Agents; 2017 Nov; 50(5):657-663. PubMed ID: 28705665
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
20. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
